期刊
MOLECULAR CANCER THERAPEUTICS
卷 17, 期 12, 页码 2756-2766出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-18-0118
关键词
-
类别
资金
- NIH [P30-ES023512]
- Sid Kyle Endowment
- Texas AgriLife Research
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023512] Funding Source: NIH RePORTER
Alveolar rhabdomyosarcoma (ARMS) patients have a poor prognosis, and this is primarily due to overexpression of the oncogenic fusion protein PAX3-FOXO1. Results of RNA - sequencing studies show that PAX3-FOXO1 represses expression of interleukin-24 (IL24), and these two genes are inversely expressed in patient tumors. PAX3-FOXO1 also regulates histone deacetylase 5 (HDAC5) in ARMS cells, and results of RNA interference studies confirmed that PAX3-FOXO1- mediated repression of IL24 is HDAC5-dependent. Knock-down of PAX3-FOXO1 decreases ARMS cell proliferation, survival, and migration, and we also observed similar responses in cells after overexpression of IL24, consistent with results reported for this tumor suppressor-like cytokine in other solid tumors. We also observed in double knockdown studies that the inhibition of ARMS cell proliferation, survival, and migration after knockdown of PAX3-FOXO1 was significantly (>75%) reversed by knockdown of IL24. Adenoviral-expressed IL24 was directly injected into ARMS tumors in athymic nude mice, and this resulted in decreased tumor growth and weight. Because adenoviral IL24 has already successfully undergone phase I in clinical trials, this represents an alternative approach (alone and/or combination) for treating ARMS patients who currently undergo cytotoxic drug therapies. (C) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据